HAZLET, N.J. - TelAve -- In this symposium, an expert faculty will discuss the data with injectable GLP-1 RAs in ASCVD patients and the place of injectable GLP-1 RAs in reduction of cardiovascular risk. The design, efficacy and safety results from the SOUL trial will be presented, as well as the latest meta-analyses with GLP-1 RAs. Cases of patients with T2D and ASCVD will be presented, and attendees will be provided with best practices incorporating evidence-based clinical decision making and patient-centered care.

Click here for more information

CHAIR

Darren McGuire, MD MHSC
Distinguished Chair in Cardiovascular Science
Distinguished Teaching Professor

More on TelAve News

• QView Medical and Eve Wellness Announce Partnership to Advance Direct-to-Consumer Breast Cancer Screening With FDA-Approved AI
• New Article Reveals Common Pricing Pitfalls in Flooring Projects — And How to Avoid Them
• Airbus Defence and Space and Omnitronics Sign MoU to Advance Interoperability in Critical Communications
• White Glove Restoration Sends "Help in Boxes" to Support Communities in Ghana
• NASA Agreements, New Ocean Exploration Applications Added to Partnerships with Defiant Space Corp and Emtel Energy USA for Solar Tech Leader: $ASTI

University of Texas Southwestern Medical Center
Dallas, Texas

FACULTY

Lawrence Letter, MD, FRCPC
Professor of Medicine and Nutritional Sciences
University of Toronto
Toronto, Ontario, Canada

Neha Pagidipati, MD, MPH
Associate Professor of Medicine
Duke University School of Medicine
Durham, North Carolina

Richard Pratley, MD
Samuel E. Crockett Chair in Diabetes Research
AdventHealth Translational Research Institute
Medical Director, AdventHealth Diabetes Institute
Orlando, Florida

Educational Objectives
- Describe the key injectable GLP-1 RA clinical trials and meta analyses in patients with T2D and high ASCVD risk
- Explain the American Diabetes Association 2025 guideline recommendations for the use of GLP-1 RAs in patients with T2D and ASCVD or multiple risk factors for ASCVD
- Interpret the evidence from the SOUL trial and describe the potential role for oral GLP-1 RA therapy in patients with T2D and high risk

Target Audience

More on TelAve News

• Chic and Secure: The Blue Luna Debuts Stylish Keychains with Purpose
• BEC Technologies Showcases Leadership in Private Broadband Ecosystem with Inclusion in UTC's Ecosystem Summary Report
• $500,000 in Stock Dividend for Shareholders in 2025 Sweetens The Pot on Success of Becoming Debt Free with No Convertible Notes or Warrants for $IQST
• Milwaukee Job Corps Center: Essential Workforce Training—Admissions Now Open
• Aissist.io Launches Hybrid AI Workforce to Solve AI Pilot Failure for Customer Support Automation

This program is intended for cardiovascular clinicians and other healthcare professionals who manage patients with T2D and ASCVD risk.

Educational Grant
Voxmedia International gratefully acknowledges the educational grant from Novo Nordisk Inc.

Accreditation and Credit Designation Statements
Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Voxmedia, LLC designates this live activity for a maximum of 1.5 AMA PRA Category Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.